Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Status:
Completed
Trial end date:
2018-01-10
Target enrollment:
Participant gender:
Summary
This is a multicenter open-label, prospective study in subjects with dark skin from one of
the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with
moderate to severe acne vulgaris on the face.
All eligible subjects will receive Adapalene 0.3% - BPO 2.5% gel (Epiduo Forte/TactuPump
Forte) once daily on whole face.
The purpose of this trial is to evaluate subject reported outcomes with the combination of
Adapalene 0.3% - BPO 2.5%, Epiduo Forte / TactuPump Forte gel, after 16 weeks of treatment of
moderate to severe acne in dark skin phototypes (IV to VI).